Integra Lifesciences Cleared to Market New Dural Graft Matrix

Integra LifeSciences Holdings Corp. (Plainsboro, NJ) has received FDA 510(k) clearance for its innovative dural graft matrix, DuraGen.

DuraGen, the newest product in Integra's line of absorbable implants, is indicated as a dura substitute for the repair of the dura mater. DuraGen allows the surgeon to provide a safe and effective method of dural repair in neurosurgical and spinal procedures. The product was recently launched in Europe, and will be introduced to hospitals in the United States late this summer through Integra NeuroCare, the neurosurgery business unit of Integra.